Compare Organon & Co. Common Stock (OGN) vs Synchrony Financial (SYF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Synchrony Financial — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Synchrony Financial trades at $71.41 (market cap $23.94B). The key difference: Synchrony Financial is far larger — about 6.6× Organon & Co. Common Stock's market cap, and Synchrony Financial pays the higher dividend (1.85%). Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Synchrony Financial for 30 Days on average.
| OGN | SYF | |
|---|---|---|
Market Cap | $3.62B | $23.94B |
Volume | 2,892,999 | 2,618,932 |
Sector | Health | Financials |
52-Week High | $13.81 | $88.47 |
52-Week Low | $5.70 | $63.78 |
Typical Hold Time | 0 Days | 30 Days |
Enterprise Value | $11.04B | $24.18B |
Dividend Yield | 0.58% | 1.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Synchrony Financial (SYF) trades at $73.59, down slightly by 0.04% on the day. The stock exhibits a bullish technical signal overall, with support near $73 and resistance at $75. Fundamentally, the company shows strong profitability with a 23.4% net income margin and a compelling valuation at a P/E of 7.55. Recent earnings have consistently beaten expectations, and strategic partnerships, like the one with OpenAI announced on August 17, 2026, highlight growth initiatives.
The outlook for SYF is positive, supported by robust analyst sentiment with a consensus price target of $87.50, implying significant upside. Key opportunities include high ROE and strategic expansions in digital finance. Risks involve potential consumer credit deterioration, as noted in broader market news on August 26, 2026, and increased investing cash outflows in 2026, which could pressure near-term liquidity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Synchrony Financial
Synchrony Financial is a premier consumer financial services company and the largest provider of private-label credit cards in the United States. Spun off from GE Capital in 2014, it operates through a unique B2B2C model, embedding its financing products within the ecosystems of major partners like Amazon, Lowe’s, and PayPal. Synchrony leverages deep data analytics and a diverse multi-platform strategy—spanning retail, health, and auto—to drive customer loyalty and provide specialized credit solutions at the point of sale.
Read more on SYF →
